

## **Call 2017: 'High throughput screening of therapeutic molecules and rare diseases'**

**The call 'High throughput screening of therapeutic molecules and rare diseases' launched by the French Foundation for rare diseases (Fondation maladies rares) supports early drug discovery by the use of compound screening.**

***Submission deadline for proposals: September 19, 2017, 5:00 pm***

### **A – Context and objectives of the call for proposals**

Development of therapies for patients living with a rare disease is an absolute priority, since for most rare diseases, no pathophysiology based therapy nor efficient treatment exist.

The French Foundation for rare diseases launches a call for proposals dedicated to 'High throughput screening of therapeutic molecules' to support projects aimed at identifying molecules with potential benefit in the treatment of rare diseases.

Projects will be based on a high throughput/content screening (HTS/HCS) approach using compound libraries, towards the discovery of active molecules 'hits' with therapeutic potential. A second step towards investing into the 'hit to lead' process to approach drug-like characteristics will be supported.

The development of the miniaturized robust and reproducible assay is considered as a crucial step and a starting point in the process of filtering out potential 'hits' to be optimized as downstream drug candidates. Moreover, the experimental design of the screening, which has key consequences on the quality of the subsequent hits selected, requires the expertise of HTS trained staff.

Then the crossroads of all skills between the medicinal chemist and the biologist, multidisciplinary teams and competences in pharmacokinetics, physico-chemistry, toxicology, chemo-computing in order to evaluate all the parameters to be optimized will allow to select best compounds with drug-like characteristics.

### **B – Content of the call**

This call for proposals is open to research projects covering all rare diseases.

For rare cancers, only projects concerning benign tumors as well as systemic rare diseases involving tumor development will be evaluated within this call.

The aim of the call is in compliance with the goals set by the International Rare Diseases Research Consortium (IRDIRC).

The principal investigator of the project must belong to a French research team, affiliated to academia (research team working in universities, other higher education institutions or research institutes) and/or to clinical/public health sector (research team working in hospitals/public health organizations).

**Prerequisite:** The project must rely on scientifically validated preliminary data. The biological model (target/process/phenotype) will have been identified and validated by the research team itself or as part of a collaborating consortium or network. Research studies must have allowed to validate an experimental model reproducing a physiological, metabolic or biochemical pathway in the disease process for which read-outs are clearly defined. Then, the project must clearly emphasize the relevance of the screening assay towards the identification of molecules to reverse the pathogenesis of the disease described.

**Assay development:**

The knowledge gained as a result of the biological model validation process will evolve into a scheme for the development of an assay to be used in high throughput / content screening.

The establishment of the assay is based on two major tasks: miniaturization and automation. This requires downscaling the experiment to adapt it to a multi-well plate (96/384 wells) format for easy automation (pipetting, detection system). For that purpose, it is also necessary to adapt biochemical, cell culture or whole organism assay conditions and the assay read-out conditions.

The optimal conditions for implementing this strategy must be tailored for the model and take into account :

- the type of assay: target or process based; biochemical, cell-based or whole organism-based assay; the biological model and the link between the model and the aimed pathology
- the detection technology employed (e.g. luminescence, fluorescence, ...)
- reagents required (e.g. cell lines, antibodies, purified proteins, enzyme substrates...)
- equipments required

Clear and measurable read-out(s) must have been identified.

Successful applicants will have the opportunity to develop a small-scale high throughput / content screening assay as a first step.

**Compound screening:**

The screening of the Prestwick chemical library [1280 small molecules, FDA approved active compounds selected for their high chemical and pharmacological diversity, known bioavailability and safety in humans] or of an equivalent library may be envisaged in order to validate the assay and to allow picking 'hits'. The screening of larger chemical/natural libraries (~10,000 compounds), such as a part of the French National Chemical Library, could be performed on the fully operational system.

**'Hit to Lead' campaign to develop lead candidates:**

'Hit to lead' optimization stages follow the identification of primary hits from screening and rely on two major steps:

1- Hits confirmation and profiling:

Objective: confirm a limited series of molecules, by complementary approaches such as confirmatory testing, dose response curves, orthogonal testing, biophysical testing, secondary screening, giving prioritization through multiple criteria such as patents, synthesis pathways, in silico profiling, etc., with the aim to rank and cluster hits.

2- Lead discovery

Objective: to evaluate the optimization potential of confirmed hits in order to select the best compounds and to provide a limited optimization of selected compounds towards a proof of concept in an animal model by combining experimental and computer-aided protocols.

May include for example:

- the evaluation of pharmacology (activity/efficacy) and physico-chemical profiles, ADME (Absorption, Distribution, Metabolism, Excretion) and toxicology properties, pharmacokinetic (PK) behavior;
- a limited testing of analogous compounds to determine a quantitative structure-activity relationship (QSAR);
- the improvement of hits affinities, metabolic half life, selectivity against other biological targets.

### **C- Conditions of experimentation:**

#### **1. Access to platforms :**

Principal investigators must contact platforms for a detailed description of services and costs that could fit the objectives of their project and to obtain assistance in optimizing the technical design: assay miniaturization/automation, choice of chemical libraries to screen, data analysis in 'hit' selection and validation, 'hit to lead' optimization stages.

The development of the miniaturized assay and the screening will be performed by an experienced academic HTS/HCS platform.

The screening platform itself either has complementary services or is closely linked with other platforms to provide the best suited ADME/PK or chemistry approaches required for 'hit to lead' development schemes.

Information about screening platforms partners of the call is available on the website (<http://fondation-maladiesrares.org/la-recherche/aide-au-financement/nos-plateformes-partenaires>).

Other partnerships between the French Foundation for rare diseases and platform(s) will remain an exception. It will be considered on the basis of case by case evaluation by the foundation in accordance with specifications of the call.

Applicant and head of platforms are invited to contact the Foundation at [criblage\\_preclinique@fondation-maladiesrares.com](mailto:criblage_preclinique@fondation-maladiesrares.com) in order to evaluate partnership modalities.

The assay will be developed in close interaction between dedicated member(s) of the research team and the platform.

A period of 6 to 18 months is required for assay development and screening. A second period of 6 to 18 months is required for hit selection and characterization (early ADME properties, analog testing). The progress of each project will be monitored and updated every 3 months by the project manager of the platform and communicated to the principal investigator.

Results and Intellectual Property data resulting from projects funded through the call will be owned by the researcher's organizations.

## 2. Technical validation:

**Technical feasibility and eligibility of the project must be checked and approved by the platform before submission.**

This procedure is mandatory and should be planned early in the process in order to ensure timely submission of the project.

A detailed timetable and budget associated with each step of the project must be provided.

### D – Scientific evaluation

#### 1. Evaluation criteria

- Relevance of the project and robustness of preliminary data and the overarching scientific plan;
- Originality and/or innovative potential of the project;
- Feasibility of the project;
- Clarity of objectives and outcomes of the project;
- Prospects in terms of future development and capitalization of emerging data;
- Integration of the project in the research program of the applicant;
- Positioning of the project in the national and international context.

#### 2. Selection

Selection will be made on a peer review mode. Proposals will be evaluated by two external, national and international, referees with a recognized expertise. Projects will then be selected by a scientific *ad hoc* committee, composed of platform representatives and members of the Scientific Advisory Board of the French foundation for rare diseases.

### E – Funding

The French Foundation for rare diseases may provide financial support for every of the following stages: the assay development and screening, the ‘hit to lead’ process for investigators who already identified promising hits from a screening campaign.

**Assay development and screening** - for a maximal amount of 25,000€ - for the setting up and validation of a miniaturized assay, the primary high throughput screening of a medium-scale chemical/natural compound library (~10,000 compounds), hit confirmation, dose-response and a report of results provided by the screening platform.

**‘Hit to Lead’ campaign** - for a maximal amount of 25,000€ - for investing into the ‘hit to lead’ process by experimental and *in silico* approaches

**Funding will cover costs of services provided by the platform and is not intended to cover equipment, running costs or personnel costs in the researcher’s laboratory.**

## F – Proposal submission and schedule of the call

To complete and submit an application form, please access to the portal “**Applicant portal**”.

Submission deadline for proposals: **September 19, 2017 (5:00 pm)**.

The provisional schedule of the call is the following:

<b>June, 2017</b>	Launch of the call
<b>September 19, 2017 (5:00 pm)</b>	Submission deadline for proposal (electronic form)
<b>October-November 2017</b>	Evaluation process
<b>December 2017</b>	Publication of the selected projects

The title of the selected projects and name of the principal investigator will be published on the website of the French Foundation for rare diseases. The summary written for a general audience may be used for communication purposes by the Foundation.

**Acknowledgement Policy:** It is required that projects funded by the French Foundation for rare diseases be acknowledged in all publications and communications. Reference(s) of the publication(s) must be sent to the foundation.

**IRDiRC policies and guidelines:** the project partners are expected to follow IRDiRC policies and guidelines. For more information see <http://www.irdirc.org>